Biopharmaceutical company ABVC BioPharma announced a significant expansion of its U.S. operations, committing to invest over $220 million in advanced manufacturing infrastructure. The strategic investment includes a previously acquired California pharmaceutical facility and plans for new 'gigafactories' designed to revolutionize botanical pharmaceutical production.
The company has already invested more than $100 million in U.S. operations, with a $60 million pharmaceutical manufacturing facility in California that supports clinical-stage drug development. The facility specializes in API processing, formulation development, and packaging for clinical trials across oncology, CNS disorders, and ophthalmology.
ABVC's planned gigafactories represent a $120 million investment, focusing on cutting-edge production technologies including vertical farming, hydroponic systems, and AI-driven environmental controls. The facilities aim to produce over 1,000 metric tons of botanical raw materials annually, potentially reducing raw material costs by 30% while creating a sustainable, traceable supply chain.
The expansion is expected to generate significant economic impact, with projections of creating over 500 new jobs across research, manufacturing, and quality control operations. The company anticipates product sales exceeding $100 million annually within five years.
CEO Uttam Patil emphasized the company's commitment to building world-class pharmaceutical infrastructure in the United States, with a focus on delivering high-quality, plant-based therapies to patients globally while establishing a secure and efficient supply chain.
